Adenosine A1 Receptor Antagonists

Compounds that bind to and block the stimulation of ADENOSINE A1 RECEPTORS.

Networked: 13 relevant articles (2 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Chemical Actions and Uses
- Pharmacologic Actions: 160
  - Molecular Mechanisms of Pharmacological Action: 24
    - Neurotransmitter Agents: 13181
      - Purinergic Agents: 10
        Purinergic Antagonists: 16
        Purinergic P1 Receptor Antagonists: 374
        Adenosine A1 Receptor Antagonists: 13
  - Physiological Effects of Drugs: 1
    - Neurotransmitter Agents: 13181
      - Purinergic Agents: 10
        Purinergic Antagonists: 16
        Purinergic P1 Receptor Antagonists: 374
        Adenosine A1 Receptor Antagonists: 13

Experts

1.	Givertz, Michael M: 2 articles (11/2010 - 01/2008)
2.	Mitrovic, Veselin: 2 articles (11/2010 - 11/2009)
3.	Hocher, Berthold: 2 articles (09/2010 - 11/2009)
4.	Lefin, Roslyn: 1 article (01/2017)
5.	Milne, Pieter J: 1 article (01/2017)
6.	Terre'Blanche, Gisella: 1 article (01/2017)
7.	van der Walt, Mietha M: 1 article (01/2017)
8.	Biesiadecki, Brandon J: 1 article (07/2014)
9.	Billman, George E: 1 article (07/2014)
10.	Carnes, Cynthia A: 1 article (07/2014)

Related Diseases

1.	Cardio-Renal Syndrome 01/01/2008 - "In this article, we review the cardiorenal syndrome, the role of adenosine in renal function, and emerging data regarding the safety and efficacy of adenosine A1 receptor antagonists in patients with advanced HF." 06/01/2013 - "Recent studies of patients with acute cardio-renal syndromes have focused on newer therapies, including phosphodiesterase inhibitors, vasopressin antagonists, adenosine A1 receptor antagonists, and renal protective dopamine. " 05/01/2006 - "This article addresses challenges in the use of diuretics, angiotensin-converting enzyme (ACE) inhibitors, and other therapies in the cardiorenal syndrome, as well as novel therapies that hold promise, such as arginine vasopressin antagonists, adenosine A1 receptor antagonists, and ultrafiltration."
2.	Ischemia 12/15/2000 - "Thus, adenosine A1 receptor antagonists have potent therapeutic potential against ischemia-reperfusion-induced dysmotility in the colon." 12/15/2000 - "This study was designed to assess whether adenosine A1 receptor antagonists [(R)-1-[(E)-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl) acryloyl]-piperidin-2-yl acetic acid (FK352) and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX)] reverse dysmotility induced by ischemia-reperfusion in the rat colon. "
3.	Heart Failure 11/01/2010 - "The direct effects of adenosine A1 receptor antagonists on haemodynamic parameters in patients with acute heart failure (HF) remain largely unknown. " 09/01/2010 - "Selective adenosine A1 receptor antagonists targeting renal microcirculation are novel pharmacologic agents that are currently under development for the treatment of acute heart failure as well as for chronic heart failure. " 11/01/2009 - "Blocking the tubuloglomerular feedback mechanism with adenosine A1 receptor antagonists seems to improve diuresis and sodium excretion without compromising the glomerular filtration rate in patients with heart failure. "
4.	Neurodegenerative Diseases (Neurodegenerative Disease) 01/01/2017 - "This pilot study concludes that para-substituted 3-cyclohexylamino-2-phenyl-imidazo[1,2-α]pyridine analogues represent an interesting scaffold to investigate further structure-activity relationships in the design of novel imidazo[1,2-α]pyridine-based adenosine A1 receptor antagonists for the treatment of neurodegenerative disorders."
5.	Hypotension (Low Blood Pressure) 03/01/2006 - "This Commentary discusses the use of selective adenosine A1 receptor antagonists for the prevention of dialysis hypotension from the perspective of the potential role of adenosine in its pathogenesis."

Related Drugs and Biologics

1.	Adenosine (Adenocard)
2.	1,3-dipropyl-8-cyclopentylxanthine
3.	Antidiuretic Hormone Receptor Antagonists
4.	Acetic Acid (Vinegar)
5.	Phosphodiesterase Inhibitors
6.	Dopamine (Intropin)
7.	Theophylline (Theon)
8.	Purinergic P1 Receptor Antagonists
9.	Adenosine A2 Receptors
10.	Sodium

Related Therapies and Procedures

1.	Therapeutics